Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)

PHASE2UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 8, 2023

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2024

Conditions

Newly Diagnosed Peripheral T-cell Lymphoma

Interventions

DRUG

Duvelisib, Chidamide

Duvelisib, 25mg, BID, PO; Chidamide, 20mg, BIW, PO;

Trial Locations (1)

RECRUITING

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan